These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23730881)

  • 1. Beyond anti-TNF-α agents in psoriatic arthritis.
    Spadaro A; Lubrano E
    Expert Rev Clin Immunol; 2013 Jun; 9(6):507-9. PubMed ID: 23730881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drugs for psoriatic arthritis.
    Caso F; Del Puente A; Peluso R; Caso P; Girolimetto N; Del Puente A; Scarpa R; Costa L
    Expert Opin Emerg Drugs; 2016; 21(1):69-79. PubMed ID: 26807876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab: A Review in Psoriatic Arthritis.
    Shirley M; Scott LJ
    Drugs; 2016 Jul; 76(11):1135-45. PubMed ID: 27299434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab: IL-17A inhibition to treat psoriatic arthritis.
    Speeckaert R; van Geel N; Lambert J; Claeys L; Delanghe JR; Speeckaert MM
    Drugs Today (Barc); 2016 Nov; 52(11):607-616. PubMed ID: 28112279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study.
    Kampylafka E; d'Oliveira I; Linz C; Lerchen V; Stemmler F; Simon D; Englbrecht M; Sticherling M; Rech J; Kleyer A; Schett G; Hueber AJ
    Arthritis Res Ther; 2018 Jul; 20(1):153. PubMed ID: 30053825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
    McInnes IB; Mease PJ; Ritchlin CT; Rahman P; Gottlieb AB; Kirkham B; Kajekar R; Delicha EM; Pricop L; Mpofu S
    Rheumatology (Oxford); 2017 Nov; 56(11):1993-2003. PubMed ID: 28968735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study.
    Kavanaugh A; McInnes IB; Mease PJ; Hall S; Chinoy H; Kivitz AJ; Wang Z; Mpofu S
    J Rheumatol; 2016 Sep; 43(9):1713-7. PubMed ID: 27307536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of tocilizumab in a patient with refractory psoriatic arthritis.
    Costa L; Caso F; Cantarini L; Del Puente A; Scarpa R; Atteno M
    Clin Rheumatol; 2014 Sep; 33(9):1355-7. PubMed ID: 24705820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel approaches to biological therapy for psoriatic arthritis.
    Boyd T; Kavanaugh A
    Expert Opin Biol Ther; 2016; 16(2):173-86. PubMed ID: 26572089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab: a promising therapeutic option in spondyloarthritis.
    Maldonado-Ficco H; Perez-Alamino R; Maldonado-Cocco JA
    Clin Rheumatol; 2016 Sep; 35(9):2151-61. PubMed ID: 27437696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel biological target for the treatment of psoriatic arthritis.
    Spadaro A; Montepaone M; Lubrano E
    Immunotherapy; 2014; 6(5):515-8. PubMed ID: 24896622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secukinumab for rheumatology: development and its potential place in therapy.
    Koenders MI; van den Berg WB
    Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Not Available].
    Perrotta FM; Lubrano E
    Reumatismo; 2016 Sep; 68(2):57-64. PubMed ID: 27608793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
    Caso F; Cantarini L; Morisco F; Del Puente A; Ramonda R; Fiocco U; Lubrano E; Peluso R; Caso P; Galeazzi M; Punzi L; Scarpa R; Costa L
    Expert Opin Biol Ther; 2015 May; 15(5):641-50. PubMed ID: 25652590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of psoriatic arthritis with secukinumab: a case series.
    Nicola S; Rolla G; Monti R; Brussino L
    J Dermatolog Treat; 2018; 29(sup1):6-8. PubMed ID: 30247936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.